Navigation Links
Par Pharmaceutical to Host Third Quarter 2008 Results Conference Call on November 7 at 9:00 am
Date:10/28/2008

WOODCLIFF LAKE, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it will host a conference call and live webcast on Friday, November 7, 2008 at 9:00 am EST to review results for the third quarter ended September 27, 2008. The Company will release results after the market closes on Thursday, November 6, 2008. The earnings release will be available on the Par website at http://www.parpharm.com.

Access to the live webcast can be made via the Company's website at http://www.parpharm.com. The dial-in numbers for the conference call will be 888-713-4214 for domestic callers and 617-213-4866 for international callers. The passcode is 32232063. A replay of the conference call will be available for two weeks approximately one hour after the call. The dial-in numbers for the replay are 888-286-8010 for domestic callers and 617-801-6888 for international callers. When prompted, the passcode is 59063488.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
2. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
3. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
4. Anadys Pharmaceuticals to Present at Bio Investor Forum
5. InfaCare Pharmaceutical Corporation Raises $28 Million in Series B Financing to Advance Its Neonatal Pipeline
6. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc.
9. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
10. Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders
11. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Watertown, MA (PRWEB) , ... August 31, 2015 ... ... ChopChop Magazine: The Fun Cooking Magazine for Kids , recently elected two ... ChopChop’s bylaws. These appointments will further ChopChop’s mission of inspiring and teaching kids ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau ... shipping costs. , “Before, a threshold of $49.00 was required to qualify for free ... qualify for free standard shipping for customers regardless of the item’s selling price.” , ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... thrombosis linked to deep vein thrombosis, study says , ... condition -- superficial vein thrombosis, or varicose veins that ... presence of a more dangerous problem. , One-quarter of ... study actually had deep vein thrombosis (DVT), a potentially ...
... metastasis, researchers say , MONDAY, July 20 (HealthDay News) ... contribute to aggressive breast cancer, new research shows. , ... of breast cancer tumors, researchers from the Genome Institute ... implicated in the development of breast cancer. , They ...
... , , , ... the "Door to Door" program for patients with multiple myeloma. Cancer Care ,s ... patients for covering transportation costs such as gasoline and taxi, bus or train ... The program is funded in part by a generous grant from ...
... , CBO Announcement Says Current Legislation Does Not ... , WASHINGTON, July 20 In response to a recent ... the Senate and House, the PFCD urges Congress to address the number-one ... , "The Senate HELP and House Ways ...
... School and Amtek, Hanover, NH may treat tumors that do ... on May 29th in the open access, peer reviewed journal ... to selectively kill tumors while protecting healthy cells. In ... as methylthioadenosine phosphorylase (MTAP) is missing in 35 to ...
... one of only four sites across the country to participate ... study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, ... therapy) for treating recurrent chest wall breast cancer. ... breast cancer on the chest wall, most commonly presenting in ...
Cached Medicine News:Health News:Vein Condition May Mask Serious Clot Disorder 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 2Health News:CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs 3Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New strategy in tumor treatment 2Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 2015 The scientific team of a ... of the leading academics in the field of aging Prof. ... in life extension for model animals - 10 fold for ... and age-related diseases, primarily, around the stability and stress resistance ... published as "Stability analysis of a model gene network links ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... Biosciences, Inc., a privately held company leading the development ... Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and ... President and Chief Scientific Officer, presented a poster about ... 17, 2010 at 9:30 a.m. CST in Chicago, IL. ...
... 2010 Reportlinker.com announces that a new market ... Global Contraceptives Industry ... the worldwide markets for Contraceptives in US$ Million ... Implants/ Injections, and Others. The report provides separate ...
Cached Medicine Technology:Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 2Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 3Reportlinker Adds Global Contraceptives Industry 2Reportlinker Adds Global Contraceptives Industry 3Reportlinker Adds Global Contraceptives Industry 4Reportlinker Adds Global Contraceptives Industry 5Reportlinker Adds Global Contraceptives Industry 6Reportlinker Adds Global Contraceptives Industry 7Reportlinker Adds Global Contraceptives Industry 8Reportlinker Adds Global Contraceptives Industry 9Reportlinker Adds Global Contraceptives Industry 10Reportlinker Adds Global Contraceptives Industry 11Reportlinker Adds Global Contraceptives Industry 12Reportlinker Adds Global Contraceptives Industry 13Reportlinker Adds Global Contraceptives Industry 14Reportlinker Adds Global Contraceptives Industry 15Reportlinker Adds Global Contraceptives Industry 16Reportlinker Adds Global Contraceptives Industry 17Reportlinker Adds Global Contraceptives Industry 18Reportlinker Adds Global Contraceptives Industry 19Reportlinker Adds Global Contraceptives Industry 20Reportlinker Adds Global Contraceptives Industry 21Reportlinker Adds Global Contraceptives Industry 22Reportlinker Adds Global Contraceptives Industry 23
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: